Sarcopenia in Cancer: Risking more than muscle loss.Citation formats

  • External authors:
  • Milan Anjanappa
  • Michael Corden

Standard

Sarcopenia in Cancer: Risking more than muscle loss. / Anjanappa, Milan; Corden, Michael; Green, Andrew; Roberts, Darren; Hoskin, Peter; Mcwilliam, Alan; Choudhury, Ananya.

In: Technical Innovations & Patient Support in Radiation Oncology, 14.10.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Anjanappa, M, Corden, M, Green, A, Roberts, D, Hoskin, P, Mcwilliam, A & Choudhury, A 2020, 'Sarcopenia in Cancer: Risking more than muscle loss.', Technical Innovations & Patient Support in Radiation Oncology.

APA

Anjanappa, M., Corden, M., Green, A., Roberts, D., Hoskin, P., Mcwilliam, A., & Choudhury, A. (Accepted/In press). Sarcopenia in Cancer: Risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology.

Vancouver

Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, Mcwilliam A et al. Sarcopenia in Cancer: Risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology. 2020 Oct 14.

Author

Anjanappa, Milan ; Corden, Michael ; Green, Andrew ; Roberts, Darren ; Hoskin, Peter ; Mcwilliam, Alan ; Choudhury, Ananya. / Sarcopenia in Cancer: Risking more than muscle loss. In: Technical Innovations & Patient Support in Radiation Oncology. 2020.

Bibtex

@article{77928422b8564f4f82946b6a85e2827a,
title = "Sarcopenia in Cancer: Risking more than muscle loss.",
abstract = "Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients.",
author = "Milan Anjanappa and Michael Corden and Andrew Green and Darren Roberts and Peter Hoskin and Alan Mcwilliam and Ananya Choudhury",
year = "2020",
month = oct,
day = "14",
language = "English",
journal = "Technical Innovations and Patient Support in Radiation Oncology ",
issn = "2405-6324",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Sarcopenia in Cancer: Risking more than muscle loss.

AU - Anjanappa, Milan

AU - Corden, Michael

AU - Green, Andrew

AU - Roberts, Darren

AU - Hoskin, Peter

AU - Mcwilliam, Alan

AU - Choudhury, Ananya

PY - 2020/10/14

Y1 - 2020/10/14

N2 - Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients.

AB - Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients.

M3 - Article

JO - Technical Innovations and Patient Support in Radiation Oncology

JF - Technical Innovations and Patient Support in Radiation Oncology

SN - 2405-6324

ER -